跳至主要内容
临床试验/CTIS2023-504519-34-01
CTIS2023-504519-34-01招募中1 期

sing live vaccines to induce beneficial innate immune training and reduce systemic inflammation in COPD patients (COPD-LIVE)

Gentofte Hospital0 个研究点目标入组 60 人开始时间: 2023年10月18日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Must have specialist verified, spirometry-confirmed, COPD., Age > 40 years, Able to give informed consent

排除标准

  • Acute febrile ilness, Oral or intravenous corticosteroid at a dose =10 mg/day over 3 months, Cardiac arythmia, Blood dyscrasia, Known allergy to either the BCG or MMR vaccines or severe adverse effects during prior vaccination., Allergy to MMR vaccine components, neomycin or egg proteins., Known prior, active or latent infection with mycobacterium tuberculosis., Pregnancy or breastfeeding, Vaccination with a live vaccine within 4 weeks, Severe immunocompromisation (HIV-1 infection, organ- or bone marrow transplantation, chemotherapy, primary immune defect, anti-cytokine therapy, immunosuppressant treatment)., Active solid or non-solid malignancy or lymphona within 2 years, excluding basal cell carcinoma

研究者

相似试验